Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pracinostat and Azacitidine in High Risk MDS
NCT03151304Phase 2Terminated
- Sponsor
- Helsinn
- Start
- Jun 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pracinostat in myelodysplastic syndrome (MDS), sponsored by Helsinn. Primary endpoint: Overall Response Rate at 36 months. Started Jun 2017; status: terminated.
02
Drugs
pracinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03151304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151304.